New offering identifies COVID-19 and Influenza infections with a single sample ELMWOOD PARK, N.J., October 20, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the […]
09
Oct
Oct
Through New York City, BioReference will be testing students, teachers and staff in nearly 1,000 NYC public schools ELMWOOD PARK, N.J., October 9, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school […]
02
Sep
Sep
The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today began testing New York City principals, teachers and other staff for COVID-19, across the five boroughs, in preparation for a safer back-to-school environment. Through a […]
01
Sep
Sep
ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples. OnkoSight AdvancedNGS testing provides targeted gene content that is aligned with the latest […]
06
Aug
Aug
GenomeXpress is a rapid genome sequencing test, reporting results within approximately seven days GAITHERSBURG, Md., Aug. 6, 2020 /PRNewswire/ — GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the launch of GenomeXpress, a rapid genome sequencing test. Verbal GenomeXpress results of pathogenic and/or likely pathogenic variants in known disease causing genes are […]
21
Jul
Jul
ELMWOOD PARK, N.J., July 21, 2020 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company, today announced that Geoff Monk, President of BioReference Laboratories, was recognized by CEO Today Magazine as one of this year’s 20 Healthcare Award winners. Every year, CEO Today Magazine identifies and honors the most respected companies and their executives who lead the way on the global stage. CEO Today Magazine’s Healthcare Awards acknowledge […]
20
Jul
Jul
CDC chooses BioReference as one of the antibody testing and service providers for national serological survey ELMWOOD PARK, N.J., July 20, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced it will accept an Indefinite Delivery Indefinite Quantity (IDIQ) contract award to provide Commercial Surge Capacity Testing for COVID-19 Emergency Response to the […]
13
Jul
Jul
BioReference initiates COVID-19 testing for all National Basketball Association players and referees, as well as team and league staff for its season restart in Orlando on July 30 ELMWOOD PARK, N.J., July 13, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), will provide COVID-19 testing oversight for the National Basketball Association’s (NBA) players […]
09
Jul
Jul
BioReference initiates COVID-19 testing for all Major League Soccer players, match officials, and Club and League employees participating in the MLS is Back Tournament MLS will support COVID-19 antibody testing for the Orlando community utilizing BioReference’s community collection program ELMWOOD PARK, N.J., July 09, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), will […]
Based on internal data, 29% of nursing home employees tested positive for antibodies Since the beginning of the COVID-19 pandemic, BioReference has performed 222,000 COVID-19 PCR and 3,500 antibody tests in over 350 facilities ELMWOOD PARK, N.J., July 1, 2020 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR […]